Systematic review of the efficacy and safety of interferon-free therapies for chronic hepatitis C in patients coinfected with the Human Immunodeficiency Virus

ABSTRACT The aim of this study was to conduct a systematic review to evaluate the efficacy and safety of interferon-free therapies for hepatitis C in patients coinfected with the Human Immunodeficiency Virus. In all, 10 clinical trials were included in a total of 1.626 patients coinfected with Hepatitis C Virus/Human Immunodeficiency Virus, mostly, carriers of genotype 1, and treated mainly for 12 or 24 weeks. Patients presented rates of approximately 91% for efficacy outcomes, while discontinuations due to adverse events were less than 3%. In this way, interferon-free therapies appear as a good option for the treatment of chronic hepatitis C in the group of patients coinfected with Human Immunodeficiency Virus.

摘要 本研究旨在开展一项系统综述，评估无干扰素治疗方案（interferon-free therapies）用于合并感染人类免疫缺陷病毒（Human Immunodeficiency Virus）的丙型肝炎患者的有效性与安全性。本研究共纳入10项临床试验，总计纳入1626例丙型肝炎病毒（Hepatitis C Virus）/人类免疫缺陷病毒合并感染者，其中绝大多数为基因1型病毒携带者，治疗周期主要为12周或24周。该类患者的有效性结局达标率约为91%，因不良事件导致的停药率不足3%。综上，无干扰素治疗方案可作为人类免疫缺陷病毒合并感染慢性丙型肝炎患者群体的优质治疗选择。